Abstract
The effect of chronic lead treatment on pituitary dopamine (DA) D2 receptors was studied by measuring (-)sulpiride-displaceable [3H]spiroperidol-binding and DA-inhibited adenylate cyclase. Receptor number was reduced in lead-exposed animals and bromocriptine was less able to inhibit cyclase activity in pituitary homogenates. In addition, the capacity of DA to inhibit the VIP-stimulated cAMP formation was decreased.
MeSH terms
-
Adenylyl Cyclase Inhibitors*
-
Adenylyl Cyclases / metabolism
-
Animals
-
Binding, Competitive
-
Bromocriptine / pharmacology
-
Cyclic AMP / biosynthesis
-
Dopamine / pharmacology
-
Female
-
Lead / toxicity*
-
Pituitary Gland / drug effects*
-
Pituitary Gland / enzymology
-
Rats
-
Rats, Inbred Strains
-
Receptors, Dopamine / drug effects*
-
Receptors, Dopamine / metabolism
-
Spiperone / metabolism
-
Sulpiride / metabolism
Substances
-
Adenylyl Cyclase Inhibitors
-
Receptors, Dopamine
-
Lead
-
Bromocriptine
-
Spiperone
-
Sulpiride
-
Cyclic AMP
-
Adenylyl Cyclases
-
Dopamine